Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology ...

TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...

A cohort study finds the risk for acne in patients on JAK inhibitors for atopic dermatitis was about 2.5 times greater than ...

Corvus Pharmaceuticals (NASDAQ:CRVS) shares surged 48% on Tuesday after the company released positive findings from a Phase 1 ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

Shares of Corvus Pharmaceuticals CRVS have skyrocketed 208.8% in a month. The massive stock price rally was observed after ...

The global atopic dermatitis market size was valued at USD 6.62 billion in 2025 and is predicted to hit around USD 12.97 billion by 2034, rising at a 7.75% CAGR, a study published by Towards ...